Nuwellis

Nuwellis Net Margin

The Net Profit Margin of Nuwellis (NUWE) as of Nov 9, 2026 is -211.86 %. In the previous year, Net Profit Margin was -127.75 % — a change of 65.85% (lower).

Net Margin

-211.86 %

YoY

65.85%

Last updated:

Net Profit Margin of Nuwellis is 2025 -211.86 % . Net Profit Margin of Nuwellis was 2024 -127.75 % . It decreases by 65.85% lower compared to the previous year.

Nuwellis's net margin stands at -211.9%, up from -246.9% several years earlier.

The Nuwellis Net Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Margin
Date
Net Margin
Jan 1, 2018
-340.78 USD
Jan 1, 2019
-328.69 USD
Jan 1, 2020
-212.82 USD
Jan 1, 2021
-246.86 USD
Jan 1, 2022
-170.02 USD
Jan 1, 2023
-227.99 USD
Jan 1, 2024
-127.75 USD
Jan 1, 2025
-211.86 USD
The Nuwellis Net Margin history
YEARNet MarginYoY
-211.86 %+65.85%
-127.75 %-43.97%
-227.99 %+34.09%
-170.02 %-31.13%
-246.86 %+16.00%
-212.82 %-35.25%
-328.69 %-3.55%
-340.78 %-9.52%
-376.64 %-69.26%
-1,225.14 %-97.28%
-45,055.93 %+419.46%
-8,673.56 %+2,251.96%
-368.78 %+2,557.10%
-13.88 %0.00%
-13.88 %-76.95%
-60.20 %+172.71%
-22.08 %+516.16%
-3.58 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Nuwellis Stock analysis

What does Nuwellis do? Nuwellis, Inc. develops, manufactures, and commercializes medical devices for ultrafiltration therapy, primarily the Aquadex SmartFlow and Aquadex FlexFlow systems. The Aquadex System includes a console with electromechanical pumps and an LCD screen, a disposable blood circuit set, and a catheter. It targets patients with fluid overload unresponsive to diuretics, indicated for adult and pediatric use from 20 kilograms. Hospitals and healthcare providers purchase these systems to manage fluid overload in patients who have failed diuretic therapy. The company focuses on selling the Aquadex System as a comprehensive solution for ultrafiltration therapy. Nuwellis markets the Aquadex SmartFlow system specifically for temporary or extended use in patients with fluid overload unresponsive to medical management. The Aquadex FlexFlow system is part of the same product line, designed for similar therapeutic applications. The company's revenue comes from the sale of the Aquadex System components, including the console, disposable blood circuit sets, and catheters. Healthcare facilities are the primary buyers, using these devices to treat patients requiring ultrafiltration therapy. The Aquadex System is positioned as a medical device solution for fluid overload cases where diuretics have failed. It consists of a console, disposable blood circuit set, and catheter, all sold together as a system. Hospitals and clinics purchase the Aquadex System to provide treatment options for patients who cannot be managed with standard diuretic therapy. The company's revenue model relies on the sale of the complete system and its disposable components to healthcare providers. Nuwellis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Nuwellis stock

Net Profit Margin of Nuwellis is -211.86 % in 2025.

Net Profit Margin of Nuwellis changed from -127.75 % to -211.86 %, representing a 65.85% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Profit Margin Nuwellis since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's Nuwellis with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Nuwellis

All Key Metrics — Nuwellis